COMP <GO>
ARWR vs CYTK // NET PROFIT MARGIN
Arrowhead Pharmaceuticals Inc. (NASDAQ) VS. Cytokinetics Incorporated (NASDAQ) • 15-METRIC TALLY: ARWR 8
— CYTK 2
▲ NET PROFIT MARGIN LEADER: ARWR
LAST: $59.57 (-0.55%) • MKT CAP: $8.46B
net-margins
-0.20%
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
net-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARWR VS. CYTK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARWR | CYTK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.10% | -35.00% | +46.10 | ARWR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 73.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.84% | -6.08% | +7.92 | ARWR | /fcf-yield <GO> |
| Operating Margin | 11.90% | -60.00% | +71.90 | ARWR | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -0.20% | -60.00% | +59.80 | ARWR | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 180.00% | 0.00 | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.60 | 0.45 | +6.15 | ARWR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | ARWR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.3 | 46.0 | -4.70 | CYTK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.87 | +0.09 | ARWR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 31.0x | -13.00 | ARWR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.46B | $8.76B | -$295.9M | CYTK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARWR REV | CYTK REV | ARWR GROSS % | CYTK GROSS % | ARWR FCF | CYTK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $829.4M | $88.0M | — | — | $156.9M | -$534.8M |
| FY 2024 | $3.6M | $18.5M | — | — | -$604.3M | -$399.8M |
| FY 2023 | $240.7M | $7.5M | — | — | -$164.7M | -$414.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARWR // BETA 0.96
CYTK // BETA 0.87